TRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases

• All current TRexBio institutional investors including Eli Lilly and Company, SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Pfizer Ventures and Alexandria Venture Investments participated in the financing, in addition to Laurion Capital
• Funding will further TRexBio’s growing portfolio of programs in immunology and inflammation
• Alexandra Cantley, Ph.D., a partner at Polaris Partners, joins the TRexBio board

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#Biotech--TRexBio Inc., a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, today announced it has completed a $26 million extension of its Series A financing in a round led by new investor Polaris Partners. This brings the total Series A funding raised by TRexBio to $85 million. Laurion Capital, and all the existing TRexBio institutional shareholders participated in the latest round including founding investor SV Health Investors, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Inc., Pfizer Ventures, and Alexandria Venture Investments.

TRexBio is leveraging its proprietary Deep Biology platform to identify novel targets for therapeutics with a focus on modulating regulatory T cell (Treg) response in human tissue. The company is advancing multiple preclinical programs. Proceeds from this financing will enable the continued expansion of the company’s platform and the advancement of multiple programs through pre-IND activities.

“TRexBio is working to redefine how immune-mediated diseases are treated,” said Johnston Erwin, TrexBio’s CEO. “We have made important progress over the last three years towards this goal growing what started as a big idea into an innovative discovery engine that has generated a robust portfolio and supports two big pharma collaborations. Our focus now is on supporting and progressing all of these programs towards the clinic.”

In conjunction with the financing, Alexandra Cantley, Ph.D., Partner at Polaris Partners will join the company’s Board of Directors. Alexander Duncan, Ph.D., Biotech Associate at Laurion Capital Management also joins as a Board Observer.

“TRexBio is leading the charge in one of the most exciting new areas in immunobiology and tissue homeostasis,” Dr. Cantley said. “I look forward to helping advance TRexBio’s exciting preclinical therapeutic programs in the inflammation space.”

The capital raise follows TRexBio’s recent announcement that it has entered into a multi-year research collaboration and licensing agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

About TRexBio

TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for immune-mediated diseases. Our powerful Deep Biology discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. TRexBio was founded in 2018, seed funded by SV Health Investors, and is headquartered in South San Francisco, California. For more information, please visit trex.bio or follow us on LinkedIn.

Ingrid Mezo
Canale Communications
301-473-4881
ingrid.mezo@canalecomm.com